ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Xilio Therapeutics Inc

Xilio Therapeutics Inc (XLO)

0,632
-0,038
( -5,67% )
Aktualisiert: 15:59:35

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
0,632
Gebot
0,64
Fragen
0,6479
Volumen
21.440
0,6315 Tagesbereich 0,6681
0,5001 52-Wochen-Bereich 1,93
Marktkapitalisierung
Handelsende
0,67
Handelsbeginn
0,6584
Letzte Trade
30
@
0.6398
Letzter Handelszeitpunkt
15:46:08
Finanzvolumen
US$ 13.841
VWAP
0,645561
Durchschnittliches Volumen (3 Mio.)
514.650
Ausgegebene Aktien
43.958.074
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,38
Gewinn pro Aktie (EPS)
-1,74
Erlöse
-
Nettogewinn
-76,4M

Über Xilio Therapeutics Inc

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immuno... Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Xilio Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XLO. The last closing price for Xilio Therapeutics was US$0,67. Over the last year, Xilio Therapeutics shares have traded in a share price range of US$ 0,5001 to US$ 1,93.

Xilio Therapeutics currently has 43.958.074 shares in issue. The market capitalisation of Xilio Therapeutics is US$29,45 million. Xilio Therapeutics has a price to earnings ratio (PE ratio) of -0.38.

XLO Neueste Nachrichten

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium PR Newswire VANCOUVER, BC, Jan. 22, 2025 USA News Group News Commentary Issued on behalf of Oncolytics...

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels...

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI 

Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities Completed...

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.06-8.670520231210.6920.71990.631715780.67492794CS
4-0.478-43.06306306311.111.27990.633311810.91267157CS
12-0.34-34.97942386830.9721.280.635146501.04876816CS
26-0.238-27.35632183910.871.540.633606011.04252798CS
52-0.0245-3.73191165270.65651.930.50015487001.13882088CS
156-12.408-95.153374233113.0414.860.492276161.39361025CS
260-14.368-95.78666666671527.950.492183742.14836129CS

XLO - Frequently Asked Questions (FAQ)

What is the current Xilio Therapeutics share price?
The current share price of Xilio Therapeutics is US$ 0,632
How many Xilio Therapeutics shares are in issue?
Xilio Therapeutics has 43.958.074 shares in issue
What is the market cap of Xilio Therapeutics?
The market capitalisation of Xilio Therapeutics is USD 29,45M
What is the 1 year trading range for Xilio Therapeutics share price?
Xilio Therapeutics has traded in the range of US$ 0,5001 to US$ 1,93 during the past year
What is the PE ratio of Xilio Therapeutics?
The price to earnings ratio of Xilio Therapeutics is -0,38
What is the reporting currency for Xilio Therapeutics?
Xilio Therapeutics reports financial results in USD
What is the latest annual profit for Xilio Therapeutics?
The latest annual profit of Xilio Therapeutics is USD -76,4M
What is the registered address of Xilio Therapeutics?
The registered address for Xilio Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Xilio Therapeutics website address?
The website address for Xilio Therapeutics is xiliotx.com
Which industry sector does Xilio Therapeutics operate in?
Xilio Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
BHATBlue Hat Interactive Entertainment Technology
US$ 0,1278
(85,22%)
540,01M
AIFFFirefly Neuroscience Inc
US$ 4,8703
(57,11%)
42,86M
OCEAOcean Biomedical Inc
US$ 0,2273
(53,58%)
246,42M
DOMHDominari Holdings Inc
US$ 8,65
(40,42%)
20,07M
TGLTreasure Global Inc
US$ 0,2633
(37,14%)
46,98M
FLNCFluence Energy Inc
US$ 6,8001
(-47,97%)
19,53M
CMCOColumbus McKinnon Corporation
US$ 20,90
(-41,09%)
783,8k
LIXTLixte Biotechnology Holdings Inc
US$ 1,49
(-34,65%)
1,33M
HYPRHyperfine Inc
US$ 1,11
(-33,53%)
1,65M
FTELFitell Corporation
US$ 1,5006
(-30,20%)
851,62k
BHATBlue Hat Interactive Entertainment Technology
US$ 0,1278
(85,22%)
540,01M
CYNCYNGN Inc
US$ 0,2426
(31,35%)
457,28M
OCEAOcean Biomedical Inc
US$ 0,2273
(53,58%)
246,42M
INABIN8bio Inc
US$ 0,3241
(19,99%)
155,34M
MGOLMGO Global Inc
US$ 0,4888
(-30,13%)
57,25M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock